Oxford starts human testing of Nipah virus vaccine
The University of Oxford has initiated human testing for an experimental vaccine against the Nipah virus, which has caused deadly outbreaks in Asia. The initial trial will assess safety and immune response and involves participants aged 18 to 55. The vaccine is based on the same technology used in AstraZeneca and Serum Institute of India's COVID-19 shots. The research is funded by the Coalition for Epidemic Preparedness Innovations. Further trials in Nipah-affected countries are anticipated.
